HI HB1013

Establishes the "Right to Try Act" allowing terminally ill patients to access investigational drugs, biological products, or devices that have completed phase one clinical trials but lack FDA approval.

Defines an "eligible patient" as someone with a terminal illness who has exhausted FDA-approved treatment options, received physician recommendation, and provided written informed consent that includes disclosure of potential risks and outcomes.

Permits manufacturers to provide investigational treatments without compensation or to charge patients for manufacturing costs, but does not require manufacturers to provide access.

Prohibits health insurance plans, government agencies, and hospitals from being required to cover costs associated with experimental treatments, and prevents state officials from blocking eligible patients' access to investigational treatments.

Shields health care providers, manufacturers, and other entities from licensing sanctions and private lawsuits if they act in good faith compliance with the chapter's requirements.